about
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionGlucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver diseaseInterferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy GroupRetreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.Immunological alterations in hepatitis C virus infection.Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseasesSurvival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological responseNT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.Early virologic response with pegylated interferons.Treatment of hepatitis C: critical appraisal of the evidence.The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).Hepatitis C virus (HCV) infection: a systemic disease.Hyperferritinemia is a risk factor for steatosis in chronic liver disease.Extrahepatic manifestations of hepatitis C virus infection.Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study.Hepatitis C and diabetes: the inevitable coincidence?The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.Halitosis: could it be more than mere bad breath?Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.Should cirrhosis change our attitude towards treating non-hepatic cancer?Osteodystrophy in chronic liver diseases.Fluoroquinolone-induced liver injury: three new cases and a review of the literature.Herbal hepatotoxicity: a hidden epidemic.HCV genotype 5: an orphan virus.Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.How to optimize HCV therapy in genotype 1 patients: predictors of response.Management of infections in cirrhotic patients: report of a consensus conference.Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?Cardiovascular diseases and HCV infection: a simple association or more?Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?Management of infections pre- and post-liver transplantation: report of an AISF consensus conference.Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey.
P50
Q27860901-3A85AC89-3667-4081-A35F-08B853E6DA17Q28539434-F9122233-A3F5-4065-A9E4-603B0DA9868EQ29620719-421D3B88-64F9-4942-97D2-EFC6141E6802Q30746310-7730EEEE-1415-4BB4-B968-32E55B2AE45DQ30892564-29CDCE87-3EDE-4A5D-872B-190FCA9C2BAAQ33412382-FDA6B5D9-FE69-493B-A7B3-AF55EC3C617CQ33800146-A88EE030-A26C-4F86-8FFE-252DF462A28FQ34507283-CC06D547-D7B5-4A1B-90C5-153AAB03EC2FQ34905429-9C1D2277-8EA8-4309-82DD-8C79D0417D91Q34934407-859D7FC6-777B-42C9-B237-4844B19BF1C6Q34998991-CCDD0FAE-ACB5-48AC-9D6E-0C71C900CC07Q35363970-649C4C0A-FF7B-481A-AD70-BDE04574BBFCQ35412591-201E6E5A-60BB-4B3E-A04A-85DFE311C049Q35848046-62A0AD27-2014-43F2-93BE-0DECB9BDA899Q35930570-BE2A6278-0FD4-4D93-B259-C685E0A215D9Q36006856-C3CA2508-59E8-4AC1-A342-B870054C808AQ36082056-95A0DC64-B30E-4976-9FEE-E9C33871F254Q36711602-0C42B06E-8F9F-4BCE-A3D0-9CC0C64F31E0Q37051567-89AEA601-B85B-4070-9AF2-C56B2CD16A72Q37182959-EA8F3546-FB33-4762-9351-32D16BAD2634Q37215790-0C68FBBA-7DD0-4A2C-B8E6-3F9906153658Q37389924-89AD3BF5-81DB-4DC5-9657-DDCAFDAB7752Q37429032-B2CB0577-1D86-4210-9168-411C75036F9EQ37432092-3DD76756-2E0B-420E-9CB8-E006C9B3DDB3Q37656511-7F3AA463-4235-4648-B2C5-06D278E0FB64Q37817834-0891D16A-2147-451B-A0C1-B2C81CF60D9BQ37833228-3BB7B751-9BBE-4D4A-A7A2-95A02EA4743FQ37958071-A04387BB-AD67-49B8-B0AB-74B3BF59B1D6Q37975457-0102F3C9-BD07-4C42-B686-CF2C3ED3ECF8Q37975927-60ECF1D3-0845-4737-A5C4-D2E9D7CE7598Q38000141-CA81B23D-1AE8-48E0-B2BE-CB4CC5983F93Q38056646-F197B887-5602-4C2D-BF10-50A52EB7C980Q38058632-24EA9D85-885F-4C55-8243-7BAB94C09CC5Q38071384-39ED9FAD-89F2-49AB-9F10-A7BD85653BABQ38135971-FD243B4D-E393-4B88-B57B-D3D11C8C579BQ38162294-1574A0D8-E278-411E-8673-68AF6F457730Q38167953-7867D1B1-A904-4C9F-B679-E1FF274C205FQ38174255-4E5C9976-0DEE-448A-A12D-F51806EE5046Q38175238-0DE024EB-A98A-4F40-8A45-EA601A5FF61DQ38223382-CBA84E55-C7DC-4F11-A10C-CC6919A2A0D9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Craxì
@ast
Antonio Craxì
@en
Antonio Craxì
@es
Antonio Craxì
@nl
Antonio Craxì
@sl
type
label
Antonio Craxì
@ast
Antonio Craxì
@en
Antonio Craxì
@es
Antonio Craxì
@nl
Antonio Craxì
@sl
altLabel
Antonio Craxì
@en
prefLabel
Antonio Craxì
@ast
Antonio Craxì
@en
Antonio Craxì
@es
Antonio Craxì
@nl
Antonio Craxì
@sl
P1053
K-9529-2016
P106
P1153
7006676701
P21
P31
P3829
P496
0000-0002-4480-9544